Replies to post #282733 on Avid Bioservices Inc (CDMO)

[JJ1223]

It remains disappointing that Steve King refuses to communicate with current and potential investors. With April approaching, it is obvious as to his intent. To read about upcoming events on the IHub message board speaks volumes on leadership. Curious as to where you got the information cj! Send it to SK, I did.

Known Upcoming Events

Jan24-26/Avid/Table#22: WCBP’17: 21st Symposium on Interface of Reg. & Analytical Sciences, WashDC http://www.casss.org/page/WCBP1700 (Theme: “Convergence & Harmonization”)

Jan17-20: Phacilitate's Immunotherapy World Conf., Miami http://www.immunotherapyforum.com
...Jan18 12:25-12:40pm: Dr. Jeff Hutchins (VP/PreClinRes), “Combination Immunotherapies - Opening the Gate: Increasing Tumor Infiltrating Activated T-Cells to Optimize & Expand the Benefits of Immune Checkpoint Therapies”

Feb6-7: GTCbio’s Immunotherapeutics & Immunomonitoring Conf., SanDiego https://www.gtcbio.com/conferences/immunotherapeutics-immunomonitoring-overview
...AGENDA: http://tinyurl.com/gmrlupq
...Feb7 2:05pm: Dr. Bruce Freimark(Res.Dir./Preclin.Oncology), “Blockade of PS Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Induction of Adaptive Immune Responses Mechanism”

Feb20-22: CHI’s 5th Translational Models in Oncology & I-O, SanFran http://www.triconference.com/Pre-Clinical-Oncology-Models
...Dr. Bruce Freimark(Dir.Res/Preclin.Oncology), “Blockade of PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”

~Mar8: FY'17Q3 (qe 1-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm

??Apr1-5: AACR 2017, WashDC http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105

Apr10-12: Immune Profiling World Congress 2017, WashDC (part of “World Vaccine Congress 2017”) http://tinyurl.com/zlr5cyj
...4-11-17 12:10pm: Dr. Jeff Hutchins(VP/PreClinRes.), “Increasing the Benefits of Immune Checkpoint Therapies Thru Increased Tumor Infiltrating Activated T-Cells”

??Jun2-6: ASCO 2017, Chicago https://am.asco.org

June12-17: CHI’s 2nd Annual Immunotherapy & Combinations Conf., Boston http://www.worldpreclinicalcongress.com/Cancer-Immunotherapy-Combinations
...Dr. Jeff Hutchins(VP/PreClinRes.): “Expansion & Activation of T-Cells via the Targeting of the Immunosuppressive Ligand PS: Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy”

~Jul13: FY'17Q4 (fye 4-30-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm

[Protector]

cj, thanks for the overview.

Observation: I don't see the word "biomarker" or "exosome" anywhere yet?

[cjgaddy]

CHI/I-O 2-21-17 Talk switched from JH to Dr.Michael.Gray, Senior Research Scientist at Peregrine. I actually noticed this chg. several days ago, didn’t think much of it, and had it queued to update iBox the next time I update.

Feb20-22 2017: “CHI’s 5th Translational Models in Oncology & Immuno-Oncology”, SanFran
“Models & Approaches to Bring Combination Therapies to the Clinic”
Part of the 24th Intl. Molecular Medicine Tri-Conference
http://www.triconference.com/Pre-Clinical-Oncology-Models
CHI = Cambridge Healthtech Institute http://www.healthtech.com
Track: TUMOR MODELS FOR CANCER IMMUNOTHERAPY
2-21-17 11:15-11:45am: Dr. Michael Gray (Sr.Res.Scientist), Peregrine Pharmaceuticals - “Case Study: Blockade of PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
SUMMARY:
Phosphatidylserine (PS) exposure in tumors induces non-inflammatory signals which contribute to an immunosuppressive environment. Antibody blockade of PS activates immune responses by promoting M1 macrophages, maturation of dendritic cells and inducing adaptive T-cell responses. PS targeting antibodies enhance the anti-tumor activity of checkpoint antibodies in preclinical tumor models.

= = = = = = = =Recall:
9-27-16 AACR-CRI/Dr. Michael Gray: Preclin. Triple-Combo Bavi+PD1+LAG3 TNBC data in TNBC (80% Compl. Regression, Stat-Sig. Incr. in Key Tumor Fighting Immune Cells)
http://tinyurl.com/zy9yv78
“...the presentation of preclinical study data demonstrating that phosphatidylserine (PS)-targeting antibodies similar to bavituximab are able to enhance the anti-tumor activity of multiple checkpoint targeting agents including anti-PD-1 & anti-LAG3 therapies in a model of triple negative breast cancer (TNBC). Data showed that 8 of the 10 (80%) animals receiving the preclinical bavituximab equivalent (ch1N11) combined with anti-PD-1 and anti-LAG3 therapies ("Triple Combination") experienced complete tumor regressions, whereas there were no animals (0/10) in the anti-PD-1 & anti-LAG3 combination treatment arm that had a complete regression. Addl. data demonstrated that the Triple Combination featuring ch1N11 led to a 99% reduction in total tumor volume at the interim analysis point (Day 25) across all animals as compared to the control arm. In addition, the Triple Combination showed a statistically significant increase in tumor growth inhibition (TGI) as compared to the anti-PD-1 & anti-LAG3 combination treatment (99% vs. 62%; p < 0.05). Peregrine's Michael J. Gray, PhD, the study's lead scientist, presented the study findings at the 2nd CRI-CIMT-EATI-AACR Intl. Cancer Immunotherapy Conf. Sept. 25-28, 2016, in NYC.”
**DR. MICHAEL GRAY: https://www.linkedin.com/in/michael-gray-18447328 “Principal Scientist, joined Peregrine 12-2014, prev=OSI, Educ=MDA"